Enrollment progress update provided on Ph 3 TERZO study of COPIKTRA (duvelisib) in adults with R/R nodal TFHL
“We are encouraged by the significant momentum in our Phase 3 TERZO trial, driven by the dedication of our investigators and strong interest from patients with R/R nTFHL,” said Dr. Christiane Langer, Senior Vice President of Clinical and Medical Affairs at Secura Bio. “Having achieved 25% patient accrual already, the study is advancing at the top end of our expectations and keeps us on track for an interim data readout in early 2027.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.